Prognostic Markers of Acute Suppurative Lung Disease

Author:

Fetlam D. L.1ORCID,Chumachenko A. G.1ORCID,Vyazmina M. D.1,Moroz V. V.1ORCID,Kuzovlev A. N.1ORCID,Pisarev V. M.1ORCID

Affiliation:

1. V.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Abstract

The mortality rate among patients with acute suppurative lung diseases (ASLD) in the ICU reaches 30%. Early, pathogenetically relevant biomarkers are needed to ensure personification and better efficacy of ASLD treatment. Numeric variations in the counts of immune system cells in patient’s blood can be viewed as such candidate biomarkers.The aim of the study. Identification of potential markers predicting ASLD outcome after community-acquired pneumonia and COVID-19.Materials and methods. The study included 216 in-hospital patients aged 18-87 with ASLD after community-acquired pneumonia with (N=81) and without (N=135) COVID-19 history.Results. Patients survival after COVID-19 was linked to lymphocyte count on Day 1 of hospital stay (hazard ratio, HR=5.9 95%CI 0.9–37.4; P=0.0188, log-rank test). In patients who had not have COVID-19, a difference in survival was associated with lymphocyte (HR=2.9 95%CI 1.0–8.4; P=0.0184, log-rank test; N=135), and monocyte counts (HR=2.7 95% CI 0.8–9.5; P=0.0196, log-rank test) on Day 1 of hospital stay. Patients’ survival after COVID-19 infection depended on SII (systemic immune-inflammation index. HR=9.3 95%CI 1.7–49.8; P=0.0124, log-rank test; N=81, SIRI (systemic inflammatory response index, HR=7.2 95%CI 1.4–36.6; P=0.0339, log-rank test; N=81) and NLR (neutrophil-to-lymphocyte ratio, HR=9.6 95%CI 1.8–52.0; P=0.0108; log-rank test; N=81) values on Day 1 of hospital stay. In patients who did not have COVID-19 SII values had no influence on survival.Conclusion. The lymphocyte count makes it possible to predict outcomes of pleural empyema, regardless of patient’s history of COVID-19, i. e. a decrease in the lymphocyte count below 1.2×10⁹ in 1 L is associated with fatal outcome. Monocyte count carries prognostic information for cases of pleural empyema without previous COVID-19 infection. As for the relative indicators, SIRI, SII and NLR values measured on Day 1 in the hospital were predictors of ASLD outcome only in patients after COVID-19 infection, i. e., higher values were associated with increased risk of death, with NLR index being the most informative. Overall severity of illness above 10 scores by CIRS was associated with an unfavorable ASLD outcome, regardless of patient’s history of COVID-19.

Publisher

FSBI SRIGR RAMS

Reference61 articles.

1. Korymasov E. A., Yablonskii P. K., Zhestkov K. G., Sokolovich E. G., Motus I.Ya., Lishenko V. V., Skryabin S. A. Suppurative lung diseases: national clinical guidelines of the Association of Thoracic Surgeons of Russia. Available at: http://thoracic.ru/ wp-content/uploads/НКР-по-лечению-нагноительных-заболеванийлегких-_ПРОЕКТ_pdf (accessed 28.05.2023). (In Russ.).

2. Garvia V, Paul M. Empyema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 29083780.

3. Stüben B. O., Plitzko G. A., Reeh M. Melling N., Izbicki J. R., Bachmann K., Tachezy M. Intrathoracic vacuum therapy for the therapy of pleural empyema-a systematic review and analysis of the literature. J Thorac Dis. 2023; 15 (2): 780–790. DOI: 10.21037/jtd-22-1188. PMID: 36910103.

4. Hassan M., Patel S., Sadaka A. S., Bedawi E. O., Corcoran J. P., Porcel J. M. Recent insights into the management of pleural infection. Int J Gen Med. 2021; 14: 3415–3429. DOI: 10.2147/IJGM.S292705. PMID: 34290522.

5. Iguina M. M., Danckers M. Thoracic empyema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 5, 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3